Literature DB >> 16418145

Validation of an overactive bladder awareness tool for use in primary care settings.

Karin S Coyne1, Teresa Zyczynski, Mary Kay Margolis, Victor Elinoff, Richard G Roberts.   

Abstract

Overactive bladder (OAB)--a syndrome characterized by urinary urgency, with or without urge incontinence, urinary frequency and nocturia--is estimated to affect 10% to 20% of the US and European populations. This study was carried out to validate a patient-administered screening awareness tool to identify patients with bothersome OAB symptoms. Patients were recruited from 12 primary care and 1 gynecology practice during regularly scheduled appointments. Enrollees completed an 8-item questionnaire assessing the amount of "bother" they associated with OAB symptoms. Clinicians then asked the patients 4 questions regarding urinary frequency, urgency, nocturia, and incontinence. If the screening was positive for symptoms of OAB or if the patient provided positive responses to the urinary symptom questions, the clinician asked additional questions regarding lifestyle and coping behaviors. The clinician then diagnosed the patient, placing him or her in the "No OAB," "Possible OAB," or "Probable OAB" category. Multivariable logistic regressions controlling for age and sex were performed to assess the applicability of the tool for identifying patients with OAB. A total of 1,299 patients were enrolled, and 1,260 provided complete data. Patients were aged 51.6+/-17.0 years, 62% were female, most (89%) were Caucasian, 22% experienced urinary urgency, and 18% experienced urge incontinence. The prevalence of Probable OAB was 12%. The c-index of the model identifying patients with a diagnosis of Probable OAB was 0.96, with a sensitivity and specificity of 98.0 and 82.7. For OAB-V8 scores >or=8, the odds ratio for Probable OAB was 95.7 (95% CI: 29.3; 312.4). The OAB-V8 performed well in helping clinicians identify patients with bothersome OAB symptoms in a primary care setting and will assist clinicians in identifying patients who may benefit from treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16418145     DOI: 10.1007/bf02850085

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  48 in total

1.  Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.

Authors:  Seyfettin Ciftci; Cuneyd Ozkurkcugil; Hasan Yilmaz; Murat Ustuner; Ufuk Yavuz; Mustafa Yuksekkaya; Mustafa Baki Cekmen
Journal:  Int Urogynecol J       Date:  2015-08-27       Impact factor: 2.894

Review 2.  Measuring urgency in clinical practice.

Authors:  Roger R Dmochowski; Mary P FitzGerald; Jean-Jacques Wyndaele
Journal:  World J Urol       Date:  2009-08-27       Impact factor: 4.226

3.  Comparison of Serum Vitamin D Levels in Relation to Bowel and Bladder Symptoms in Women with Vulvar Diseases.

Authors:  Carolyn W Swenson; Megan O Schimpf; Stacy B Menees; Hope K Haefner; Mitchell B Berger
Journal:  Int J Vitam Nutr Res       Date:  2019-02-12       Impact factor: 1.784

4.  Overactive bladder in men: a practical approach.

Authors:  Alexandra L Millman; Douglas C Cheung; Cian Hackett; Dean Elterman
Journal:  Br J Gen Pract       Date:  2018-06       Impact factor: 5.386

5.  An Internet survey of demographic and health factors associated with risk of sexual dysfunction in women who have sex with women.

Authors:  Alan W Shindel; Tami S Rowen; Tzu-Chun Lin; Chin-Shang Li; Patricia A Robertson; Benjamin N Breyer
Journal:  J Sex Med       Date:  2012-02-29       Impact factor: 3.802

6.  Prevalence of overactive bladder and stress urinary incontinence in women who have sex with women: an internet-based survey.

Authors:  Renea M Sturm; Benjamin N Breyer; Chin-Shang Li; Leslee L Subak; Jeannete S Brown; Alan W Shindel
Journal:  J Womens Health (Larchmt)       Date:  2014-10-14       Impact factor: 2.681

7.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

8.  Methodology for a trial of brain-centered versus anticholinergic therapy in women with urgency urinary incontinence.

Authors:  Yuko M Komesu; Rebecca G Rogers; Robert E Sapien; Ronald M Schrader; Timothy Simmerman-Sierra; Andrew R Mayer; Loren H Ketai
Journal:  Int Urogynecol J       Date:  2016-10-17       Impact factor: 2.894

9.  Correlation of pelvic organ prolapse staging with lower urinary tract symptoms, sexual dysfunction, and quality of life.

Authors:  Serife Esra Cetinkaya; Fulya Dokmeci; Omer Dai
Journal:  Int Urogynecol J       Date:  2013-03-28       Impact factor: 2.894

10.  A clinical perspective on electronically collecting patient-reported outcomes at the point-of-care for overactive bladder.

Authors:  Darren Desantis; Richard J Baverstock; Andrea Civitarese; R Trafford Crump; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.